Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction * Inoperable locally advanced disease, resections with R0, R1 or R2 outcome or metastatic disease. * CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor tissue sample. * Measurable and/or non-measurable disease as defined according to RECIST v1.1 * Age ≥ 18 years * Written informed consent * ECOG performance status (PS) 0-1 * Life expectancy \> 3 months Exclusion Criteria: * Prior hypersensitivity reaction or intolerance to one of the compounds of the study treatment * Known HIV infection or known symptomatic hepatitis (A, B, C) * Clinical symptoms of cerebral metastases * Pregnancy or breastfeeding * Patients treated with any bisphosphonate-based therapeutic for any indication during the previous year * Hypocalcemia that requires medication. Corrected (adjusted for serum albumin) serum calcium \< 8 mg/dl (2 mmol/L) or \> 12 mg/dL (3.0 mmol/L)